

Fig. 1




Fig. 2

PH9H5 VH (SEQ ID NO:4)

EVQLLESGGLVQPGGSLRLSCAASGFTSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSV
KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGLTVTVSS

PH9L3 VL (SEQ ID NO:3)

EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG
SGSGTDFTLTISLLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK

Fig. 3




Fig. 4




Fig. 5





Fig. 6

Food Intake in DIO mice post Compound1




TWO-way RM ANOVA, Tukey's

* $p < 0.05$ Vehicle vs. all groups

$p < 0.05$ Vehicle vs Compound1
1.0, 3.0, and 7.5nmol/kg

Fig. 7

BW change in DIO mice post Compound1



TWO-way RM ANOVA, Tukey's

* $p < 0.05$ Vehicle vs. all groups

$p < 0.05$ Vehicle vs. Compound1 1.0, 3.0,
7.5 nmol/kg and Dulaglutide

& $p < 0.05$ Vehicle vs. all Compound1 groups

Fig. 8

Food Intake in DIO mice post Compound1




Fig. 9

BW change in DIO mice post Compound1





Fig. 10






Fig. 11

Fig. 12

OXM-mAb conjugates Ex Vivo Human Plasma Stability
human GLP-1R cAMP assay




Fig. 13

OXM-mAb conjugates Ex Vivo Cyno Plasma Stability
human GLP-1R cAMP assay




Fig. 14





Fig. 15



*p<0.05, versus respective baseline

^p<0.05, versus 7.5 nmol/kg

Two-Way ANOVA RM, Tukey's